Comment on 'SARS-CoV-2 suppresses anticoagulant and fibrinolytic gene expression in the lung'
- PMID: 35014954
- PMCID: PMC8752089
- DOI: 10.7554/eLife.74268
Comment on 'SARS-CoV-2 suppresses anticoagulant and fibrinolytic gene expression in the lung'
Abstract
Mast et al. analyzed transcriptome data derived from RNA-sequencing (RNA-seq) of COVID-19 patient bronchoalveolar lavage fluid (BALF) samples, as compared to BALF RNA-seq samples from a study investigating microbiome and inflammatory interactions in obese and asthmatic adults (Mast et al., 2021). Based on their analysis of these data, Mast et al. concluded that mRNA expression of key regulators of the extrinsic coagulation cascade and fibrinolysis were significantly reduced in COVID-19 patients. Notably, they reported that the expression of the extrinsic coagulation cascade master regulator Tissue Factor (F3) remained unchanged, while there was an 8-fold upregulation of its cognate inhibitor Tissue Factor Pathway Inhibitor (TFPI). From this they conclude that "pulmonary fibrin deposition does not stem from enhanced local [tissue factor] production and that counterintuitively, COVID-19 may dampen [tissue factor]-dependent mechanisms in the lungs". They also reported decreased Activated Protein C (aPC) mediated anticoagulant activity and major increases in fibrinogen expression and other key regulators of clot formation. Many of these results are contradictory to findings in most of the field, particularly the findings regarding extrinsic coagulation cascade mediated coagulopathies. Here, we present a complete re-analysis of the data sets analyzed by Mast et al. This re-analysis demonstrates that the two data sets utilized were not comparable between one another, and that the COVID-19 sample set was not suitable for the transcriptomic analysis Mast et al. performed. We also identified other significant flaws in the design of their retrospective analysis, such as poor-quality control and filtering standards. Given the issues with the datasets and analysis, their conclusions are not supported.
Keywords: COVID-19; SARS-CoV-2; coagulation; human; infectious disease; microbiology.
© 2022, FitzGerald and Jamieson.
Conflict of interest statement
EF, AJ No competing interests declared
Figures



Comment in
-
Response to comment on 'SARS-CoV-2 suppresses anticoagulant and fibrinolytic gene expression in the lung'.Elife. 2022 Jan 11;11:e74951. doi: 10.7554/eLife.74951. Elife. 2022. PMID: 35014952 Free PMC article.
Comment on
-
SARS-CoV-2 suppresses anticoagulant and fibrinolytic gene expression in the lung.Elife. 2021 Mar 8;10:e64330. doi: 10.7554/eLife.64330. Elife. 2021. PMID: 33683204 Free PMC article.
Similar articles
-
Response to comment on 'SARS-CoV-2 suppresses anticoagulant and fibrinolytic gene expression in the lung'.Elife. 2022 Jan 11;11:e74951. doi: 10.7554/eLife.74951. Elife. 2022. PMID: 35014952 Free PMC article.
-
Lung Epithelial Cell Transcriptional Regulation as a Factor in COVID-19-associated Coagulopathies.Am J Respir Cell Mol Biol. 2021 Jun;64(6):687-697. doi: 10.1165/rcmb.2020-0453OC. Am J Respir Cell Mol Biol. 2021. PMID: 33740387 Free PMC article.
-
SARS-CoV-2 suppresses anticoagulant and fibrinolytic gene expression in the lung.Elife. 2021 Mar 8;10:e64330. doi: 10.7554/eLife.64330. Elife. 2021. PMID: 33683204 Free PMC article.
-
Coagulation, fibrinolysis, and fibrin deposition in acute lung injury.Crit Care Med. 2003 Apr;31(4 Suppl):S213-20. doi: 10.1097/01.CCM.0000057846.21303.AB. Crit Care Med. 2003. PMID: 12682443 Review.
-
Role of lungs in the hemostasis system (review of literature).Klin Lab Diagn. 2021 Jul 16;66(7):411-416. doi: 10.51620/0869-2084-2021-66-7-411-416. Klin Lab Diagn. 2021. PMID: 34292683 Review. English.
Cited by
-
Targeting thromboinflammation in COVID-19 - A narrative review of the potential of C1 inhibitor to prevent disease progression.Mol Immunol. 2022 Oct;150:99-113. doi: 10.1016/j.molimm.2022.08.008. Epub 2022 Aug 22. Mol Immunol. 2022. PMID: 36030710 Free PMC article. Review.
-
Status of major hemostatic components in the setting of COVID-19: the effect on endothelium, platelets, coagulation factors, fibrinolytic system, and complement.Ann Hematol. 2023 Jun;102(6):1307-1322. doi: 10.1007/s00277-023-05234-1. Epub 2023 Apr 19. Ann Hematol. 2023. PMID: 37074380 Free PMC article. Review.
-
Coagulopathy and adverse outcomes in hospitalized patients with COVID-19: results from the NOR-Solidarity trial.Res Pract Thromb Haemost. 2023 Dec 7;8(1):102289. doi: 10.1016/j.rpth.2023.102289. eCollection 2024 Jan. Res Pract Thromb Haemost. 2023. PMID: 38292350 Free PMC article.
-
Response to comment on 'SARS-CoV-2 suppresses anticoagulant and fibrinolytic gene expression in the lung'.Elife. 2022 Jan 11;11:e74951. doi: 10.7554/eLife.74951. Elife. 2022. PMID: 35014952 Free PMC article.
References
-
- CDC Current Cigarette Smoking Among Adults in the United States. Centers for Disease Control and Prevention. 2020. [September 26, 2021]. https://www.cdc.gov/tobacco/data_statistics/fact_sheets/adult_data/cig_s...
-
- CDC Most Recent National Asthma Data. 2021a. [September 26, 2021]. https://www.cdc.gov/asthma/most_recent_national_asthma_data.htm
-
- CDC Obesity is a Common, Serious, and Costly Disease. Centers for Disease Control and Prevention. 2021b. [September 9, 2021]. https://www.cdc.gov/obesity/data/adult.html
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous